Intech Investment Management LLC Acquires New Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Intech Investment Management LLC purchased a new stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 24,382 shares of the company’s stock, valued at approximately $439,000.

A number of other hedge funds have also recently made changes to their positions in TEVA. Thrivent Financial for Lutherans raised its position in shares of Teva Pharmaceutical Industries by 21.8% during the 3rd quarter. Thrivent Financial for Lutherans now owns 224,511 shares of the company’s stock valued at $4,046,000 after buying an additional 40,218 shares in the last quarter. Coronation Fund Managers Ltd. bought a new position in Teva Pharmaceutical Industries in the second quarter valued at $1,334,000. Point72 Asset Management L.P. raised its position in Teva Pharmaceutical Industries by 38.0% during the second quarter. Point72 Asset Management L.P. now owns 1,319,217 shares of the company’s stock valued at $21,437,000 after purchasing an additional 363,217 shares in the last quarter. Lighthouse Investment Partners LLC bought a new stake in Teva Pharmaceutical Industries during the second quarter worth about $6,825,000. Finally, WCM Investment Management LLC purchased a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter worth about $1,051,000. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts recently weighed in on the company. JPMorgan Chase & Co. boosted their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, October 21st. UBS Group upped their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Finally, Barclays upped their price target on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $19.67.

Insider Activity at Teva Pharmaceutical Industries

In related news, EVP Christine Fox sold 19,388 shares of the stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the transaction, the executive vice president now directly owns 44,104 shares in the company, valued at $744,034.48. This trade represents a 30.54 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.55% of the stock is currently owned by corporate insiders.

Teva Pharmaceutical Industries Price Performance

TEVA stock opened at $16.65 on Tuesday. The company has a debt-to-equity ratio of 2.57, a current ratio of 0.89 and a quick ratio of 0.61. Teva Pharmaceutical Industries Limited has a 1 year low of $9.35 and a 1 year high of $19.31. The firm has a 50-day moving average of $17.54 and a 200 day moving average of $17.36. The company has a market cap of $18.86 billion, a P/E ratio of -19.59, a PEG ratio of 1.30 and a beta of 0.87.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.